Stay updated on CA-4948 in CNS Lymphoma: Clinical Trial
Sign up to get notified when there's something new on the CA-4948 in CNS Lymphoma: Clinical Trial page.

Latest updates to the CA-4948 in CNS Lymphoma: Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check15 days agoNo Change Detected
- Check22 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference1.0%
- Check29 days agoNo Change Detected
- Check36 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference1%
- Check43 days agoChange DetectedThe website has been updated from version 2.14.1 to 2.14.2.SummaryDifference0.1%
- Check50 days agoChange DetectedA new clinical trial (CA-4948-101) has been added to evaluate the safety and efficacy of emavusertib in combination with ibrutinib for patients with relapsed or refractory primary central nervous system lymphoma, while a previous study on the same topic has been removed.SummaryDifference56%
- Check58 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check65 days agoChange DetectedThe website has updated the 'type of intervention' feature from version 2.13.3 to 2.14.0, indicating a significant change in this functionality.SummaryDifference0.2%
Stay in the know with updates to CA-4948 in CNS Lymphoma: Clinical Trial
Enter your email address, and we'll notify you when there's something new on the CA-4948 in CNS Lymphoma: Clinical Trial page.